2014

Johnson & Johnson Reports 2013 Second-Quarter Results: Sales of $17.9 Billion increased 8.5% Versus 2012 Second Quarter;

Second-Quarter EPS was $1.33

Excluding Special Items, 2013 Second-Quarter EPS of $1.48 Increased 13.8%*

 

 

NEW BRUNSWICK, N.J., July 16, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $17.9 billion for the second quarter of 2013, an increase of 8.5% as compared to the second quarter of 2012.  Operational results increased 10.0% and the negative impact of currency was 1.5%.  Domestic sales increased 8.0%.  International sales increased 9.0%, reflecting operational growth of 11.8% and a negative currency impact of 2.8%. Sales included the impact of the acquisition of Synthes, Inc., net of the divestiture of the DePuy trauma business. Excluding this impact, worldwide operational sales growth was 5.6%.

Net earnings and diluted earnings per share for the second quarter of 2013 were $3.8 billion and $1.33, respectively.  The second quarter results included the gain on the sale of the equity interest owned in Elan Corporation, plc, as previously disclosed. Second quarter 2013 net earnings included after-tax special items of approximately $0.5 billion, related to litigation expenses, integration and transaction costs associated with the acquisition of Synthes, Inc, and program costs associated with the DePuy ASRTM Hip. Second quarter 2012 net earnings included after-tax special items of approximately $2.2 billion as shown in the accompanying reconciliation of non-GAAP financial measures. Excluding these special items, net earnings for the current quarter were $4.3 billion and diluted earnings per share were $1.48, representing increases of 17.7% and 13.8%, respectively, as compared to the same period in 2012.*  

"Our strong second-quarter results reflect the progress we've made against our near-term priorities of delivering on our financial commitments, restoring a reliable supply of over-the-counter products to consumers, continuing the successful integration of Synthes and building on the momentum in our pharmaceutical business," said Alex Gorsky, Chairman and Chief Executive Officer.  "Our talented colleagues at Johnson & Johnson continue to bring meaningful innovations to patients and consumers around the world and have positioned us well to deliver sustainable growth."

The Company increased its earnings guidance for full-year 2013 to $5.40 - $5.47 per share. The Company's guidance excludes the impact of special items.

Worldwide Consumer sales of $3.7 billion for the second quarter represented an increase of 1.1% versus the prior year consisting of an operational increase of 1.7% and a negative impact from currency of 0.6%.  Domestic sales increased 1.0%.  International sales increased 1.1%, which reflected an operational increase of 2.0% and a negative currency impact of 0.9%.

Positive contributors to operational results were upper respiratory over-the-counter medicines; TYLENOL® and MOTRIN® analgesics; international sales of LISTERINE® mouthwash; baby care products and women's sanitary protection products.

Worldwide Pharmaceutical sales of $7.0 billion for the second quarter represented an increase of 11.7% versus the prior year with operational growth of 12.9% and a negative impact from currency of 1.2%.  Domestic sales increased 9.1%.  International sales increased 14.1% which reflected an operational increase of 16.5% and a negative currency impact of 2.4%. 

Primary contributors to operational sales growth were REMICADE® (infliximab) and SIMPONI® (golimumab),  biologics approved for the treatment of a number of immune-mediated inflammatory diseases; STELARA® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis; INVEGA® SUSTENNA®/XEPLION® (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the acute and maintenance treatment of schizophrenia in adults; VELCADE® (bortezomib), a treatment for multiple myeloma;  PREZISTA® (darunavir), a treatment for HIV; and sales of recently launched products.

The strong sales results of recently launched products included ZYTIGA® (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer; XARELTO® (rivaroxaban), an oral anticoagulant; and INCIVO® (telaprevir), a direct acting antiviral protease inhibitor, for the treatment of genotype-1 chronic hepatitis C virus.

During the quarter, the U.S. Food and Drug Administration (FDA) approved SIMPONI® (golimumab) for the treatment of moderately to severely active ulcerative colitis in adult patients who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates, oral corticosteroids, azathioprine, or 6-mercaptopurine.

Additionally, the FDA granted Breakthrough Therapy Designation for daratumumab for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double refractory to a PI and IMiD. Daratumumab is an investigational human CD38 monoclonal antibody licensed from Genmab A/S.

In addition, a New Drug Application was submitted to the FDA under Breakthrough Therapy Designation for the use of ibrutinib in previously treated patients with chronic lymphocytic leukemia /small lymphocytic lymphoma, and for use in previously treated patients with mantle cell lymphoma.

Also during the quarter, a Marketing Authorization Application was submitted to the European Medicines Agency seeking approval for simeprevir (TMC435). Simeprevir is a new generation NS3/4A protease inhibitor, administered as one 150mg capsule once daily in combination with peginterferon alfa and ribavirin, indicated for the treatment of genotype 1 or genotype 4 chronic hepatitis C in adult patients with compensated liver disease (including cirrhosis), with or without HIV-1 co-infection, who are treatment naive or who have failed previous interferon therapy (pegylated or non-pegylated) with or without ribavirin.

The Committee for Medical Products for Human Use of The European Medicines Agency granted a positive opinion on two variations relating to the use of VELCADE® (bortezomib). The first recommendation was for the use of VELCADE® as retreatment in adult patients who have previously responded to treatment with the same medicine. The second recommendation was as induction therapy in combination with dexamethasone or dexamethasone and thalidomide for adult patients with previously untreated multiple myeloma that are eligible for high-dose chemotherapy with haematological stem cell transplantation. In addition, the European Commission approved a new twice daily (BID) dosing of INCIVO® (telaprevir), a direct acting antiviral protease inhibitor, in combination with pegylated-interferon and ribavirin for naive and previous treatment experienced patients.

A definitive agreement was signed in June to acquire Aragon Pharmaceuticals, Inc., a privately-held, pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers. The acquisition includes Aragon's androgen receptor antagonist program.  Aragon's lead product candidate is a second generation androgen receptor signaling inhibitor, ARN-509, in Phase 2 development for castration resistant prostate cancer.

Worldwide Medical Devices and Diagnostics sales of $7.2 billion for the second quarter represented an increase of 9.6% versus the prior year consisting of an operational increase of 12.0% and a negative currency impact of 2.4%.  Domestic sales increased 9.8%.  International sales increased 9.4%, which reflected an operational increase of 13.7% and a negative currency impact of 4.3%. Sales included the impact of the acquisition of Synthes, Inc., net of the divestiture of the DePuy trauma business. Excluding this impact, worldwide operational sales growth was 0.5%.

Primary contributors to operational growth were sales from the acquisition of Synthes, Inc., in the Orthopaedics business; Biosense Webster's electrophysiology products in the Cardiovascular Care business; Vision Care's 1-Day ACUVUE® TRUEYE and 1-Day ACUVUE® MOIST® disposable contact lenses; and biosurgical and international sales of energy products in the Specialty Surgery business. 

During the quarter, the FDA granted Premarket Approval for the SEDASYS® System, the first computer-assisted personalized sedation system for healthy patients undergoing sedation during routine colonoscopy and esophagogastroduodenoscopy procedures.

About Johnson & Johnson   
Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 128,000 employees at more than 275 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Net earnings and diluted earnings per share excluding special items are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the financial schedules accompanying this press release and can be found in the Investor Relations section of the Company's website at www.investor.jnj.com.

Johnson & Johnson will conduct a conference call with financial analysts to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliation of non-GAAP financial measures, and sales of key products/franchises.  Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development can be found on the Company's website at www.jnj.com.

NOTE TO INVESTORS 

(This release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson.  Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; significant adverse litigation or government action; impact of business combinations; financial distress and bankruptcies experienced by significant customers and suppliers; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and sovereign risk; disruptions due to natural disasters; manufacturing difficulties or delays; complex global supply chains with increasing regulatory requirements; and product efficacy or safety concerns resulting in product recalls or regulatory action. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2012.  Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.investor.jnj.com or on request from Johnson & Johnson.  Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

 

Johnson & Johnson and Subsidiaries




















Supplementary Sales Data








































(Unaudited; Dollars in Millions)

SECOND QUARTER


SIX MONTHS






                      Percent
                      Change







                        Percent
                        Change


2013


2012


Total


Operations


Currency


2013


2012


Total


Operations


Currency

Sales to customers by




















segment of business








































Consumer




















    U.S.

$  1,326


1,313


1.0

%

1.0


-


$  2,674


2,629


1.7

%

1.7


-

    International

2,332


2,306


1.1


2.0


(0.9)


4,659


4,585


1.6


2.9


(1.3)


3,658


3,619


1.1


1.7


(0.6)


7,333


7,214


1.6


2.4


(0.8)





















Pharmaceutical




















    U.S.

3,377


3,094


9.1


9.1


-


6,848


6,120


11.9


11.9


-

    International

3,648


3,197


14.1


16.5


(2.4)


6,945


6,304


10.2


12.4


(2.2)


7,025


6,291


11.7


12.9


(1.2)


13,793


12,424


11.0


12.1


(1.1)





















Med Devices & Diagnostics




















    U.S.

3,243


2,953


9.8


9.8


-


6,449


5,830


10.6


10.6


-

    International

3,951


3,612


9.4


13.7


(4.3)


7,807


7,146


9.2


12.9


(3.7)


7,194


6,565


9.6


12.0


(2.4)


14,256


12,976


9.9


12.0


(2.1)





















U.S.

7,946


7,360


8.0


8.0


-


15,971


14,579


9.5


9.5


-

International

9,931


9,115


9.0


11.8


(2.8)


19,411


18,035


7.6


10.2


(2.6)

Worldwide

$17,877


16,475


8.5

%

10.0


(1.5)


$35,382


32,614


8.5

%

9.9


(1.4)

 

Johnson & Johnson and Subsidiaries




















Supplementary Sales Data








































(Unaudited; Dollars in Millions)

SECOND QUARTER


SIX MONTHS








Percent Change










Percent Change




2013


2012


Total


Operations


Currency


2013


2012


Total


Operations


Currency

Sales to customers by




















geographic area








































U.S.

$  7,946


7,360


8.0

%

8.0


-


$15,971


14,579


9.5

%

9.5


-





















Europe

4,672


4,165


12.2


11.4


0.8


9,153


8,359


9.5


8.8


0.7

Western Hemisphere excluding U.S.

1,905


1,728


10.2


14.0


(3.8)


3,688


3,442


7.1


11.5


(4.4)

Asia-Pacific, Africa

3,354


3,222


4.1


11.0


(6.9)


6,570


6,234


5.4


11.4


(6.0)

International

9,931


9,115


9.0


11.8


(2.8)


19,411


18,035


7.6


10.2


(2.6)





















Worldwide

$17,877


$16,475


8.5

%

10.0


(1.5)


$35,382


$32,614


8.5

%

9.9


(1.4)

 

Johnson & Johnson and Subsidiaries










Condensed Consolidated Statement of Earnings 




















(Unaudited; in Millions Except Per Share Figures)

SECOND QUARTER












2013


2012


Percent




Percent




Percent


Increase


Amount


to Sales


Amount


to Sales


(Decrease)

Sales to customers

$     17,877


100.0


$     16,475


100.0


8.5

Cost of products sold

5,489


30.7


5,143


31.2


6.7

Selling, marketing and administrative expenses

5,376


30.1


4,965


30.1


8.3

Research and development expense

1,946


10.9


1,766


10.7


10.2

In-process research and development

-


-


429


2.6



Interest (income) expense, net

101


0.6


129


0.8



Other (income) expense, net

172


0.9


2,008


12.2



Earnings before provision for taxes on income

4,793


26.8


2,035


12.4


135.5

Provision for taxes on income

960


5.4


627


3.9


53.1

Net earnings

$       3,833


21.4


$       1,408


8.5


172.2











Net earnings per share (Diluted)

$         1.33




$         0.50




166.0











Average shares outstanding (Diluted)

2,893.0




2,798.2















Effective tax rate

20.0

%



30.8

%














Adjusted earnings before provision for taxes and net earnings (1)








  Earnings before provision for taxes on income

$       5,359


30.0


$       4,646


28.2


15.3

  Net earnings

$       4,289


24.0


$       3,644


22.1


17.7

  Net earnings per share (Diluted)

$         1.48




$         1.30




13.8

  Effective tax rate

20.0

%



21.6

%














(1) See Reconciliation of Non-GAAP Financial Measures.










 

Johnson & Johnson and Subsidiaries










Condensed Consolidated Statement of Earnings 




















(Unaudited; in Millions Except Per Share Figures)

SIX MONTHS












2013


2012


Percent




Percent




Percent


Increase


Amount


to Sales


Amount


to Sales


(Decrease)

Sales to customers

$     35,382


100.0


$     32,614


100.0


8.5

Cost of products sold

11,043


31.2


10,058


30.8


9.8

Selling, marketing and administrative expenses

10,599


30.0


9,980


30.6


6.2

Research and development expense

3,730


10.5


3,411


10.5


9.4

In-process research and development

64


0.2


429


1.3



Interest (income) expense, net

205


0.6


259


0.8



Other (income) expense, net

687


1.9


1,397


4.3



Earnings before provision for taxes on income

9,054


25.6


7,080


21.7


27.9

Provision for taxes on income

1,724


4.9


1,762


5.4


(2.2)

Net earnings

$       7,330


20.7


$       5,318


16.3


37.8











Net earnings per share (Diluted)

$         2.55




$         1.91




33.5











Average shares outstanding (Diluted)

2,878.8




2,792.4















Effective tax rate

19.0

%



24.9

%














Adjusted earnings before provision for taxes and net earnings (1)








  Earnings before provision for taxes on income

$     10,429


29.5


$       9,574


29.4


8.9

  Net earnings

$       8,396


23.7


$       7,448


22.8


12.7

  Net earnings per share (Diluted)

$         2.92




$         2.67




9.4

  Effective tax rate

19.5

%



22.2

%














(1) See Reconciliation of Non-GAAP Financial Measures.










 

Johnson & Johnson and Subsidiaries














Reconciliation of Non-GAAP Financial Measures





























Second Quarter


% Incr. /



Six Months YTD


% Incr. /


(Dollars in Millions Except Per Share Data)

2013


2012


(Decr.)



2013


2012


(Decr.)
















Earnings before provision for taxes on income - as reported

$   4,793


2,035


135.5

%


$   9,054


$   7,080


27.9

%















Intangible asset write-downs

-


939





-


939


















Litigation expenses

375


669





904


669


















Synthes integration/transaction costs and currency related

122


574





380


457


















In-process research and development

-


429





64


429


















DePuy ASR™Hip program

69


-





82


-


















Other

-


-





(55)


-


















Earnings before provision for taxes on income - as adjusted

$   5,359


4,646


15.3

%


$ 10,429


9,574


8.9

%















Net Earnings - as reported

$   3,833


1,408


172.2

%


$   7,330


5,318


37.8

%















Intangible asset write-downs

-


717





-


717


















Litigation expenses

308


611





699


611


















Synthes integration/transaction costs and currency related

87


564





270


458


















In-process research and development

-


344





42


344


















DePuy ASR™Hip program

61


-





91


-


















Other

-


-





(36)


-


















Net Earnings - as adjusted 

$   4,289


3,644


17.7

%


$   8,396


7,448


12.7

%















Diluted Net Earnings per share - as reported

$     1.33


0.50


166.0

%


$     2.55


1.91


33.5

%















Intangible asset write-downs

-


0.26





-


0.26


















Litigation expenses

0.10


0.22





0.24


0.22


















Synthes integration/transaction costs and currency related

0.03


0.20





0.09


0.16


















In-process research and development

-


0.12





0.02


0.12


















DePuy ASR™Hip program

0.02


-





0.03


-


















Other

-


-





(0.01)


-


















Diluted Net Earnings per share - as adjusted 

$     1.48


1.30


13.8

%


$     2.92


2.67


9.4

%





























The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes 



on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.






 


REPORTED SALES vs. PRIOR PERIOD ($MM)


SECOND QUARTER


SIX MONTHS






% Change






% Change



2013


2012

Reported

Operational (1)

Currency



2013


2012

Reported

Operational (1)

Currency

CONSUMER SEGMENT (2) (4)
















BABY CARE
















US


$          106


106

0.0%

0.0%

-



$          209


205

2.0%

2.0%

-

Intl


480


472

1.7%

3.8%

-2.1%



941


913

3.1%

5.7%

-2.6%

WW


586


578

1.4%

3.1%

-1.7%



1,150


1,118

2.9%

5.0%

-2.1%

ORAL CARE
















US


149


159

-6.3%

-6.3%

-



307


314

-2.2%

-2.2%

-

Intl


257


249

3.2%

4.3%

-1.1%



502


481

4.4%

5.8%

-1.4%

WW


406


408

-0.5%

0.2%

-0.7%



809


795

1.8%

2.6%

-0.8%

OTC (3)
















US


290


247

17.4%

17.4%

-



644


538

19.7%

19.7%

-

Intl


641


636

0.8%

0.9%

-0.1%



1,330


1,296

2.6%

3.0%

-0.4%

WW


931


883

5.4%

5.4%

0.0%



1,974


1,834

7.6%

7.9%

-0.3%

SKIN CARE
















US


463


471

-1.7%

-1.7%

-



916


924

-0.9%

-0.9%

-

Intl


445


442

0.7%

1.0%

-0.3%



894


896

-0.2%

0.3%

-0.5%

WW


908


913

-0.5%

-0.4%

-0.1%



1,810


1,820

-0.5%

-0.3%

-0.2%

WOMEN'S HEALTH
















US


84


80

5.0%

5.0%

-



165


173

-4.6%

-4.6%

-

Intl


327


322

1.6%

3.4%

-1.8%



647


638

1.4%

4.1%

-2.7%

WW


411


402

2.2%

3.6%

-1.4%



812


811

0.1%

2.2%

-2.1%

WOUND CARE/OTHER (3)
















US


234


250

-6.4%

-6.4%

-



433


475

-8.8%

-8.8%

-

Intl


182


185

-1.6%

-1.4%

-0.2%



345


361

-4.4%

-4.0%

-0.4%

WW


416


435

-4.4%

-4.3%

-0.1%



778


836

-6.9%

-6.7%

-0.2%

















TOTAL CONSUMER
















US


1,326


1,313

1.0%

1.0%

-



2,674


2,629

1.7%

1.7%

-

Intl


2,332


2,306

1.1%

2.0%

-0.9%



4,659


4,585

1.6%

2.9%

-1.3%

WW


$       3,658


3,619

1.1%

1.7%

-0.6%



$       7,333


7,214

1.6%

2.4%

-0.8%

































See footnotes at end of schedule






































Supplemental Sales Information












2012



2013



Q1


Q2

Q3

Q4

FY



Q1

OTC











US


291


247

263

273

1,074



354

Intl


660


636

653

743

2,692



689

WW


951


883

916

1,016

3,766



1,043












WOUND CARE/OTHER











US


225


250

214

195

884



199

Intl


176


185

163

152

676



163

WW


401


435

377

347

1,560



362

 


REPORTED SALES vs. PRIOR PERIOD ($MM)


SECOND QUARTER


SIX MONTHS






% Change






% Change



2013


2012

Reported

Operational (1)

Currency



2013


2012

Reported

Operational (1)

Currency

PHARMACEUTICAL SEGMENT (2) (4)
















IMMUNOLOGY
















US


$       1,578


1,471

7.3%

7.3%

-



$       3,217


2,924

10.0%

10.0%

-

Intl


663


448

48.0%

51.5%

-3.5%



1,228


890

38.0%

40.9%

-2.9%

WW


2,241


1,919

16.8%

17.6%

-0.8%



4,445


3,814

16.5%

17.2%

-0.7%

REMICADE
















US 


926


890

4.0%

4.0%

-



1,896


1,772

7.0%

7.0%

-

US Exports (5)


332


366

-9.3%

-9.3%

-



681


744

-8.5%

-8.5%

-

Intl


414


267

55.1%

58.2%

-3.1%



695


28

31.6%

34.0%

-2.4%

WW


1,672


1,523

9.8%

10.3%

-0.5%



3,272


3,044

7.5%

7.9%

-0.4%

SIMPONI
















US


87


63

38.1%

38.1%

-



181


127

42.5%

42.5%

-

Intl


88


62

41.9%

48.3%

-6.4%



231


114

*

*

-4.5%

WW


175


125

40.0%

43.2%

-3.2%



412


241

71.0%

73.5%

-2.5%

STELARA
















US


233


152

53.3%

53.3%

-



459


281

63.3%

63.3%

-

Intl


138


96

43.8%

45.4%

-1.6%



258


188

37.2%

38.4%

-1.2%

WW


371


248

49.6%

50.2%

-0.6%



717


469

52.9%

53.4%

-0.5%

OTHER IMMUNOLOGY
















US


-


-

-

-

-



-


-

-

-

-

Intl


23


23

0.0%

1.1%

-1.1%



44


60

-26.7%

-26.1%

-0.6%

WW


23


23

0.0%

1.1%

-1.1%



44


60

-26.7%

-26.1%

-0.6%

INFECTIOUS DISEASES
















US


259


237

9.3%

9.3%

-



497


479

3.8%

3.8%

-

Intl


711


551

29.0%

30.2%

-1.2%



1,288


1,064

21.1%

22.2%

-1.1%

WW


970


788

23.1%

23.9%

-0.8%



1,785


1,543

15.7%

16.5%

-0.8%

INCIVO
















US


-


-

-

-

-



-


-

-

-

-

Intl


172


102

68.6%

71.8%

-3.2%



334


234

42.7%

45.4%

-2.7%

WW


172


102

68.6%

71.8%

-3.2%



334


234

42.7%

45.4%

-2.7%

INTELENCE
















US


44


42

4.8%

4.8%

-



91


85

7.1%

7.1%

-

Intl


59


49

20.4%

21.0%

-0.6%



101


86

17.4%

18.0%

-0.6%

WW


103


91

13.2%

13.5%

-0.3%



192


171

12.3%

12.6%

-0.3%

PREZISTA
















US


196


166

18.1%

18.1%

-



363


326

11.3%

11.3%

-

Intl


239


207

15.5%

16.0%

-0.5%



439


371

18.3%

18.7%

-0.4%

WW


435


373

16.6%

16.9%

-0.3%



802


697

15.1%

15.3%

-0.2%

OTHER INFECTIOUS DISEASES
















US


19


29

-34.5%

-34.5%

-



43


68

-36.8%

-36.8%

-

Intl


241


193

24.9%

25.8%

-0.9%



414


373

11.0%

11.9%

-0.9%

WW


260


222

17.1%

17.9%

-0.8%



457


441

3.6%

4.3%

-0.7%

















 


REPORTED SALES vs. PRIOR PERIOD ($MM)


SECOND QUARTER


SIX MONTHS






% Change






% Change



2013


2012

Reported

Operational (1)

Currency



2013


2012

Reported

Operational (1)

Currency

















NEUROSCIENCE
















US


626


658

-4.9%

-4.9%

-



1,372


1,332

3.0%

3.0%

-

Intl


1,054


1,056

-0.2%

3.8%

-4.0%



2,052


2,029

1.1%

4.6%

-3.5%

WW


1,680


1,714

-2.0%

0.4%

-2.4%



3,424


3,361

1.9%

4.0%

-2.1%

CONCERTA/METHYLPHENIDATE
















US


85


146

-41.8%

-41.8%

-



224


343

-34.7%

-34.7%

-

Intl


130


122

6.6%

8.9%

-2.3%



247


233

6.0%

7.9%

-1.9%

WW


215


268

-19.8%

-18.7%

-1.1%



471


576

-18.2%

-17.4%

-0.8%

INVEGA
















US


76


76

0.0%

0.0%

-



147


145

1.4%

1.4%

-

Intl


74


66

12.1%

18.3%

-6.2%



135


118

14.4%

19.9%

-5.5%

WW


150


142

5.6%

8.4%

-2.8%



282


263

7.2%

9.7%

-2.5%

INVEGA SUSTENNA/ XEPLION
















US


158


120

31.7%

31.7%

-



322


220

46.4%

46.4%

-

Intl


132


75

76.0%

75.0%

1.0%



252


136

85.3%

84.4%

0.9%

WW


290


195

48.7%

48.3%

0.4%



574


356

61.2%

60.9%

0.3%

RISPERDAL CONSTA
















US


107


110

-2.7%

-2.7%

-



213


223

-4.5%

-4.5%

-

Intl


229


245

-6.5%

-3.7%

-2.8%



458


493

-7.1%

-4.9%

-2.2%

WW


336


355

-5.4%

-3.5%

-1.9%



671


716

-6.3%

-4.8%

-1.5%

OTHER NEUROSCIENCE
















US


200


206

-2.9%

-2.9%

-



466


401

16.2%

16.2%

-

Intl


489


548

-10.8%

-5.5%

-5.3%



960


1,049

-8.5%

-3.7%

-4.8%

WW


689


754

-8.6%

-4.8%

-3.8%



1,426


1,450

-1.7%

1.8%

-3.5%

ONCOLOGY
















US


206


119

73.1%

73.1%

-



405


226

79.2%

79.2%

-

Intl


679


467

45.4%

48.1%

-2.7%



1,274


956

33.3%

35.8%

-2.5%

WW


885


586

51.0%

53.2%

-2.2%



1,679


1,182

42.0%

44.0%

-2.0%

VELCADE
















US


-


-

-

-

-



-


-

-

-

-

Intl


379


318

19.2%

22.7%

-3.5%



732


671

9.1%

12.1%

-3.0%

WW


379


318

19.2%

22.7%

-3.5%



732


671

9.1%

12.1%

-3.0%

ZYTIGA
















US


174


113

54.0%

54.0%

-



335


213

57.3%

57.3%

-

Intl


221


119

85.7%

85.2%

0.5%



404


219

84.5%

84.4%

0.1%

WW


395


232

70.3%

70.0%

0.3%



739


432

71.1%

71.1%

0.0%

OTHER ONCOLOGY
















US


32


6

*

*

-



70


13

*

*

-

Intl


79


30

*

*

-7.4%



138


66

*

*

-6.0%

WW


111


36

*

*

-6.1%



208


79

*

*

-5.0%

















 


REPORTED SALES vs. PRIOR PERIOD ($MM)


SECOND QUARTER


SIX MONTHS






% Change






% Change



2013


2012

Reported

Operational (1)

Currency



2013


2012

Reported

Operational (1)

Currency

TOTAL OTHER
















US


708


609

16.3%

16.3%

-



1,357


1,159

17.1%

17.1%

-

Intl


541


675

-19.9%

-19.9%

0.0%



1,103


1,365

-19.2%

-18.6%

-0.6%

WW


1,249


1,284

-2.7%

-2.7%

0.0%



2,460


2,524

-2.5%

-2.2%

-0.3%

ACIPHEX/PARIET
















US


97


104

-6.7%

-6.7%

-



200


200

0.0%

0.0%

-

Intl


59


128

-53.9%

-54.0%

0.1%



108


254

-57.5%

-57.3%

-0.2%

WW


156


232

-32.8%

-32.8%

0.0%



308


454

-32.2%

-32.1%

-0.1%

PROCRIT/EPREX
















US


190


232

-18.1%

-18.1%

-



423


436

-3.0%

-3.0%

-

Intl


145


169

-14.2%

-14.6%

0.4%



290


341

-15.0%

-15.3%

0.3%

WW


335


401

-16.5%

-16.7%

0.2%



713


777

-8.2%

-8.3%

0.1%

XARELTO
















US


189


49

*

*

-



347


76

*

*

-

Intl


-


-

-

-

-



-


-

-

-

-

WW


189


49

*

*

-



347


76

*

*

-

OTHER
















US


232


224

3.6%

3.6%

-



387


447

-13.4%

-13.4%

-

Intl


337


378

-10.8%

-10.5%

-0.3%



705


770

-8.4%

-7.4%

-1.0%

WW


569


602

-5.5%

-5.3%

-0.2%



1,092


1,217

-10.3%

-9.7%

-0.6%

















TOTAL PHARMACEUTICAL
















US


3,377


3,094

9.1%

9.1%

-



6,848


6,120

11.9%

11.9%

-

Intl


3,648


3,197

14.1%

16.5%

-2.4%



6,945


6,304

10.2%

12.4%

-2.2%

WW


$       7,025


6,291

11.7%

12.9%

-1.2%



$     13,793


12,424

11.0%

12.1%

-1.1%

















 


REPORTED SALES vs. PRIOR PERIOD ($MM)


SECOND QUARTER


SIX MONTHS






% Change






% Change



2013


2012

Reported

Operational (1)

Currency



2013


2012

Reported

Operational (1)

Currency

MEDICAL DEVICES AND DIAGNOSTICS (2)
















CARDIOVASCULAR CARE
















US


$          204


195

4.6%

4.6%

-



$          402


371

8.4%

8.4%

-

Intl


325


309

5.2%

9.6%

-4.4%



640


615

4.1%

8.0%

-3.9%

WW


529


504

5.0%

7.7%

-2.7%



1,042


986

5.7%

8.1%

-2.4%

DIABETES CARE
















US


259


337

-23.1%

-23.1%

-



542


689

-21.3%

-21.3%

-

Intl


330


336

-1.8%

-0.5%

-1.3%



647


654

-1.1%

0.2%

-1.3%

WW


589


673

-12.5%

-11.8%

-0.7%



1,189


1,343

-11.5%

-10.9%

-0.6%

DIAGNOSTICS
















US


241


258

-6.6%

-6.6%

-



489


511

-4.3%

-4.3%

-

Intl


242


256

-5.5%

-1.5%

-4.0%



471


515

-8.5%

-4.7%

-3.8%

WW


483


514

-6.0%

-4.0%

-2.0%



960


1,026

-6.4%

-4.5%

-1.9%

INFECTION PREVENTION/OTHER
















US


95


99

-4.0%

-4.0%

-



180


215

-16.3%

-16.3%

-

Intl


139


131

6.1%

12.3%

-6.2%



266


259

2.7%

8.2%

-5.5%

WW


234


230

1.7%

5.2%

-3.5%



446


474

-5.9%

-2.9%

-3.0%

ORTHOPAEDICS
















US 


1,274


873

45.9%

45.9%

-



2,535


1,656

53.1%

53.1%

-

Intl


1,111


755

47.2%

52.4%

-5.2%



2,235


1,465

52.6%

56.3%

-3.7%

WW


2,385


1,628

46.5%

48.9%

-2.4%



4,770


3,121

52.8%

54.5%

-1.7%

SPECIALTY SURGERY
















US


331


336

-1.5%

-1.5%

-



650


663

-2.0%

-2.0%

-

Intl


325


310

4.8%

7.5%

-2.7%



633


611

3.6%

6.2%

-2.6%

WW


656


646

1.5%

2.8%

-1.3%



1,283


1,274

0.7%

1.9%

-1.2%

SURGICAL CARE 
















US


577


602

-4.2%

-4.2%

-



1,108


1,195

-7.3%

-7.3%

-

Intl


1,011


1,038

-2.6%

0.6%

-3.2%



1,988


2,070

-4.0%

-1.0%

-3.0%

WW


1,588


1,640

-3.2%

-1.2%

-2.0%



3,096


3,265

-5.2%

-3.3%

-1.9%

VISION CARE
















US


262


253

3.6%

3.6%

-



543


530

2.5%

2.5%

-

Intl


468


477

-1.9%

6.4%

-8.3%



927


957

-3.1%

4.1%

-7.2%

WW


730


730

0.0%

5.4%

-5.4%



1,470


1,487

-1.1%

3.5%

-4.6%

















TOTAL MEDICAL DEVICES AND DIAGNOSTICS
















US


3,243


2,953

9.8%

9.8%

-



6,449


5,830

10.6%

10.6%

-

Intl


3,951


3,612

9.4%

13.7%

-4.3%



7,807


7,146

9.2%

12.9%

-3.7%

WW


$       7,194


6,565

9.6%

12.0%

-2.4%



$     14,256


12,976

9.9%

12.0%

-2.1%

















 

* Percentage greater than 100%
(1) Operational growth excludes the effect of currency
(2) Select areas (unaudited)
(3) Nutritionals now reflected in Wound Care/Other, previously reported in OTC/Nutritionals
(4) Prior year amounts have been reclassified to conform to current year product disclosure
(5) Reported as U.S. sales


SOURCE Johnson & Johnson



RELATED LINKS
http://www.jnj.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.